Lenalidomide/dexamethasone improves response and prolongs time to progression, even in patients with IgA multiple myeloma: A sub-analysis of the MM-009/010 studies

被引：4
|
作者：
Foa, Robert [1 ]
Weber, Donna [2 ]
Dimopoulos, Meletios [3 ]
Olesnyckyj, Marta [4 ]
Yu, Zhinuan [4 ]
Zeldis, Jerome [4 ]
Knight, Robert [4 ]
Chanan-Khan, Asher Alban [5 ]
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Athens, Sch Med, GR-11527 Athens, Greece
[4] Celgene Corp, Summit, NJ USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4839.4839
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4839
引用
收藏
页码：284B / 284B
页数：1
相关论文
共 22 条
  • [21] Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moreau, Philippe
    Palumbo, Antonio
    Corradini, Paolo
    Cavo, Michele
    Delforge, Michel
    Weisel, Katja C.
    Ocio, Enrique M.
    Cafro, Annamaria
    Rollig, Christoph
    Knop, Stefan
    de Arriba, Felipe
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Watkins, Latisha
    Herring, Jennifer
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    BLOOD, 2015, 126 (23)
  • [22] Elotuzumab plus lenalidomide and dexamethasone (ELd) in relapsed/refractory multiple myeloma (RRMM): ELOQUENT-2 post-hoc analysis of progression-free survival (PFS), tumor regrowth by time from diagnosis and prior lines of therapy, and median duration of response (DOR)
    Weisel, K.
    Dimopoulos, M. A.
    Palumbo, A.
    Richardson, P.
    Mateos, M. -, V
    Moreau, P.
    Gupta, M.
    Sheng, J.
    Passey, C.
    Sy, O.
    Katz, J.
    Lonial, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 223 - 223
123